Therapeutic considerations in the management of patients with heparin-induced thrombocytopenia.
Tong
Lisa M
LM
Comprehensive Hemostasis and Antithrombotic Service, University of California, San Francisco CA 94143, USA. lmtong@itsa.ucsf.edu
Mendez
Marisa N
MN
D000925:Anticoagulants / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines; D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives; D006801:Humans; D010875:Pipecolic Acids / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011355:Prodrugs / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D006629:Hirudins; D010875:Pipecolic Acids; D011134:Polysaccharides; D011355:Prodrugs; D011994:Recombinant Proteins; D013449:Sulfonamides; C426686:ximelagatran; D006493:Heparin; D001120:Arginine; D013917:Thrombin; C031942:argatroban; D000077425:Fondaparinux; C083544:lepirudin